These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1465 related articles for article (PubMed ID: 16011533)

  • 21. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression.
    Papasavvas E; Sandberg JK; Rutstein R; Moore EC; Mackiewicz A; Thiel B; Pistilli M; June RR; Jordan KA; Gross R; Maino VC; Nixon DF; Montaner LJ
    J Infect Dis; 2003 Sep; 188(6):873-82. PubMed ID: 12964119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
    Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA; Hartman KE; Dragileva E; Dondero M; Gebretsadik T; Shintani A; Peiperl L; Valentine F; Kalams SA
    J Infect Dis; 2006 Sep; 194(5):661-5. PubMed ID: 16897665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dynamics of T lymphocyte subsets in HAART treated AIDS patients with successful suppression of HIV replication and different CD4 + T cell restoration].
    Qiu ZF; Li TS; Ruan GR; Han Y; Xie J; Zuo LY; Li YL; Wang AX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):386-90. PubMed ID: 16900640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of CD8+ T lymphocytes in chronic HIV-1 subtype A infection in Rwandan women.
    Jiang Y; Karita E; Castor D; Jolly PE
    Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51 Suppl():OL737-43. PubMed ID: 16171573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection.
    Huang KH; Loutfy MR; Boulet S; Toma E; Tsoukas CM; Bernard NF
    Antivir Ther; 2009; 14(3):381-92. PubMed ID: 19474472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
    Gori A; Trabattoni D; Bandera A; Saresella M; Marchetti G; Gazzola L; Biasin M; Rhodes J; McDade H; Panebianco R; Galli M; Moroni M; Ferrante P; Thomas N; Franzetti F; Bray D; Clerici M
    Antivir Ther; 2004 Aug; 9(4):603-14. PubMed ID: 15456092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in T-cell subpopulations during four years of suppression of HIV-1 replication in patients with advanced disease.
    Lepej SZ; Begovac J; Vince A
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):351-9. PubMed ID: 16553807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of CD8(+) T-cell subsets in HIV-infected rapid progressor children versus non--rapid progressor children.
    Paul ME; Shearer WT; Kozinetz CA; Lewis DE
    J Allergy Clin Immunol; 2001 Aug; 108(2):258-64. PubMed ID: 11496243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
    J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.
    Lange CG; Valdez H; Medvik K; Asaad R; Lederman MM
    Clin Immunol; 2002 Feb; 102(2):154-61. PubMed ID: 11846457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.
    Migueles SA; Laborico AC; Shupert WL; Sabbaghian MS; Rabin R; Hallahan CW; Van Baarle D; Kostense S; Miedema F; McLaughlin M; Ehler L; Metcalf J; Liu S; Connors M
    Nat Immunol; 2002 Nov; 3(11):1061-8. PubMed ID: 12368910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
    Onen NF; Overton ET; Presti R; Blair C; Powderly WG; Mondy K
    HIV Med; 2009 Aug; 10(7):439-46. PubMed ID: 19459993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.